Lisa Warner, MD
Family Medicine · Pickerington, OHNPI 1790048452
Payments from drug & device makers
Across 168 payments — averaging $12.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$454
- AbbVie$273
- AstraZeneca$249
- Takeda Pharmaceuticals U.S.A., Inc.$171
- Pfizer$171
- Lilly USA, LLC$136
- plus $727 from 24 others
What the payments were for
- Food & beverage$2,181100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $454 |
| AbbVie(2 entities) | 16 | $273 |
| AstraZeneca | 17 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $171 |
| Pfizer | 14 | $171 |
| Lilly USA, LLC | 10 | $136 |
| GSK | 8 | $114 |
| Astellas Pharma US Inc | 5 | $80 |
| Amgen(2 entities) | 5 | $74 |
| Amarin Pharma, Inc. | 3 | $51 |
| Regeneron Healthcare Solutions, Inc. | 3 | $44 |
| Merck | 3 | $37 |
| Sanofi-aventis U.S. LLC | 3 | $35 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Vertex | 1 | $23 |
| Novartis | 2 | $23 |
| Johnson & Johnson | 2 | $22 |
| Genentech USA, Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Valeritas, Inc. | 1 | $20 |
| Vivus LLC | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Nevro Corp. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $4 |
How this compares
$2,181 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $136,744 |
| EliquisApixaban | 70 | $73,896 |
| MounjaroTirzepatide | 44 | $59,330 |
| TrulicityDulaglutide | 25 | $39,982 |
| RybelsusSemaglutide | 35 | $36,459 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $29,411 |
| TradjentaLinagliptin | 17 | $19,254 |
| WegovySemaglutide | 11 | $14,226 |
| JanuviaSitagliptin Phosphate | 12 | $13,991 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $12,199 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $6,974 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $5,880 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,675 |
| Atorvastatin Calcium | 498 | $5,154 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $4,860 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $454 | $187,428134 claims |
| Lilly USA, LLCMounjaro, Trulicity | $136 | $99,31269 claims |
| PfizerEliquis | $171 | $73,89670 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $114 | $51,51782 claims |
| Boehringer IngelheimTradjenta | $12 | $19,25417 claims |
| MerckJanuvia | $37 | $13,99112 claims |
| AstraZenecaSymbicort | $249 | $5,88023 claims |
| AbbVieSynthroid | $273 | $2,79942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Pickerington
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.